Skip to main content
Premium Trial:

Request an Annual Quote

BC Platforms, Medaffcon Partner for Data Harmonization

NEW YORK (GenomeWeb) – BC Platforms is joining with with medical evidence provider Medaffcon in an effort to harmonize genomic and clinical data gathered from multiple sources, the companies said today. Financial terms of the partnership were not disclosed.

Medaffcon specializes in generating medical evidence from biobank-based research. Under the partnership with Switzerland-based BC Platforms, Medaffcon will be leveraging the global biobank analytics platform, the companies said.

"The collaboration will expand our capabilities of accessing and combining different Finnish and international data sources to advance research," Jaana Ahlamaa, Medaffcon's medical and market access director, said in a statement.

"Our goal is to combine our global platform to leverage Medaffcon's extensive expertise in key markets in order to utilize real-world evidence faster and more effectively," added BC Platforms CEO Tero Silvola.

Espoo, Finland-based Medaffcon is a wholly owned subsidiary of German pharmaceutical distributor the Phoenix Group.

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.